reason report
result increas financi guidanc indic tafasitamab
would file eu next year ahead expect posit
updat led us increas scenario-weight tafasitamab
forecast increas confid
tafasitamab approv us probabl
eu probabl forecast morphosi
break-even increas price target
r/r dlbcl tafasitamab us file track year-end eu
file r/r diffus larg cell lymphoma r/r
dlbcl eu file base complet l-mind trial
surpris investor previous compani indic would
like wait data active-control b-mind trail
becam avail recent compani becom
posit prospect europ yesterday morphosi
announc letter intent submit ema earli juli
plan complet submiss base preced
construct interact european regulatori author
updat increas chanc earli eu approv
could enhanc discuss potenti collabor ex-
us commerci right collabor like provid up-front
mileston payment unlock addit valu asset compar
morphosi commerci
l-mind file track synthet control arm data readi
morphosi reiter guidanc tafasitamab bla submiss
year-end time compani also present headlin data
virtual lenalidomide-onli control arm submit
bla packag expect data match histor trial
respons rate short durat respons see initi
detail would increas investor confid
likelihood us tafasitamab approv next year
b-mind biomark disclos low baselin peripher blood
bendamustin vs rituxan bendamustin previous amend
includ respons patient sub popul undisclos
novel biomark co-primari endpoint see note being-
mind regulatori hurdl trial amend lower approv risk
dcf analysi discount rate
net debt total capit
year price history/av daili volume mil mor gy
compani inform svb leerink llc research
revenu mm
pleas refer page import disclosur price chart analyst certif
r/r dlbcl patient nk cell per microlit blood may
sub-optimal respons standard therapi rituxan
morphosi unpublish preclin data support increas
rel efficaci tafasitamab group compani believ
biomark repres approxim patient studi entri
b-mind trial readout interim progression-fre surviv
entir popul also biomark subpopul
full data expect disclosur help view
b-mind less necessari l-mind serv basi approv
us eu two trial target patient popul
l-mind durabl respons hard match tafasitamab
bendamustin combin tafasitamab lenalidomid
like prefer tafasitamab bendamustin point b-
mind may serv upsid surpris biomark popul
superior benefit control arm group indistinguish
non-nk low popul trial integr valuat
morphosi stock time
revenu beat expens consensu morphosi
report revenu includ gsk mileston payment
tremfya royalti expens
less consensu sg
also consensu compani report
slightli narrow loss per share compar consensu
primarili due gsk mileston estim morphosi
suffici cash least two year oper although
expect compani rais addit capit immedi
pre-launch period tafasitamab
guidanc increas gsk mileston morphosi increas
prior guidanc revenu
primarili account previou gsk mileston payment
compani reiter proprietari reduc
expect ebit loss guidanc
model updat pt adr updat
morphosi model trend quarter guidanc
updat assum faster time eu tafasitamab launch
model probabl tafasitamab approv us
approv approv probabl
tafasitamab approv eu approv
approv scenario-weight global tafasitamab sale
grow
peak total revenu forecast morphosi increas
year beyond adjust revenu forecast
recent consensu beyond also increas oper
expens forecast beyond account requir
commerci buildout earlier tafasitamab launch loss per share
forecast increas slightli decreas
forecast break-even signific posit ep rang
loss per share estim
greater consensu posit earn
estim significantli higher consensu later
year base chang new price target dcf
price target morphosi mor us adr rate
stock outperform morphosi german biopharmaceut compani long legaci
innov therapeut monoclon antibodi discoveri develop histor morphosi
taken care path build broad portfolio skinni collabor bigger
biopharma compani result potenti low-to-mid singl digit royalti
product collabor final come fruition first reach
market tremfya begin gener royalti morphosi larger
basi compani valu howev morphosi wholly-own tafasitamab
hematolog malign tafasitamab shown impress data single-arm phase ii trial
patient transplant-inelig relaps refractori dlbcl endors
us fda data appear suffici acceler approv tafasitamab
abl gener revenu rang still
potenti develop larger popul sever differ form non-hodgkin
lymphoma nhl import asset mor stock royalti jnj op il-
antibodi psoriasi estim worth today could increas
substanti revenu exce perform product indic
royalty-bear product agreement contribut anoth compani outstand
cash reserv add anoth give total valu per share
price target mor base dcf methodolog cash
flow termin growth driver forecast royalti tremfya
risk-adjust sale tafasitamab risk-adjust royalti assum
discount rate base compani wacc addit factor mor cash balanc
valuat
risk view outlook valuat morphosi includ failur obtain approv
tafasitamab either us ex-u jurisdict base l-mind forecast
product also subject risk better-than-expect market share gain
competit brand product roch polatuzumab lack willing
physician patient chang new treatment tafasitamab long-stand
treatment option payer us europ could also refus reimburs expens
combin tafasitamab plu revlimid could potenti cost
year treatment addit morphosi current sole sourc incom royalti tremfya
could lower expect due chang highli competit immunolog treatment
market risk morphosi includ develop regulatori disappoint
partner out-licens antibodi two product fail compani valuat
would reduc approxim
pipelin program includ current model
pipelin program exclud current
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
collabor annouc
partnership ex us right
svb leerink llc research compani file
million
royalti mileston po adjust
svb leerink llc research compani file
million
sale
 total revenu
sg total revenu
svb leerink llc research compani file
mm
pv flow
equiti
debt
